Novartis AG (LON:0K9E)
London
· Delayed Price · Currency is GBP · Price in USD 119.94
-0.00 (-0.00%)
At close: Jun 27, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 1.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 18.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Innovative Medicines | 50.32B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Innovative Medicines Growth | 12.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sandoz | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sandoz Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular, Renal And Metabolic | 8.58B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular, Renal And Metabolic Growth | 30.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunology | 9.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunology Growth | 18.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience | 4.75B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Neuroscience Growth | 29.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology | 14.74B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Growth | 16.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Established Brands | 12.96B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Established Brands Growth | -11.86% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 1.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 18.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 1.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 18.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 1.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 18.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2011 - 2018 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2011 - 2018 |
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Innovative Medicines Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Innovative Medicines Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sandoz Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sandoz Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gross Income by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2011 - 2018 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2011 - 2018 |
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Innovative Medicines Gross Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Innovative Medicines Gross Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sandoz Gross Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sandoz Gross Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Gross Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Gross Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Revenue (Post-Q2 2023 Reporting) | 21.15B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Revenue (Post-Q2 2023 Reporting) Growth | 20.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Revenue (Post-Q2 2023 Reporting) | 15.56B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Revenue (Post-Q2 2023 Reporting) Growth | 3.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) | 10.02B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth | 6.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Canada and Latin America Revenue (Post-Q2 2023 Reporting) | 3.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth | 7.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Canada and Latin America Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Canada and Latin America Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Gilenya Revenue | 552.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gilenya Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Tasigna Revenue | 1.67B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Tasigna Revenue Growth | -7.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Lucentis Revenue | 1.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Lucentis Revenue Growth | -33.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cosentyx Revenue | 6.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cosentyx Revenue Growth | 21.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Entresto Revenue | 7.82B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Entresto Revenue Growth | 25.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|